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RESEARCH
Comparative evaluation of clinical manifestations and risk 
of death in patients admitted to hospital with covid-19 and 
 seasonal influenza: cohort study
Yan Xie,1,2,3 Benjamin Bowe,1,2,3 Geetha Maddukuri,4 Ziyad Al-Aly1,3,4,5,6
ABSTRACT
OBJECTIVE 
To comparatively examine differences in risk of clinical 
manifestations and death among people admitted to 





US Department of Veterans Affairs.
PARTICIPANTS
Patients admitted to hospital with covid-19 between 
1 February 2020 and 17 June 2020 (n=3641) 
and seasonal influenza between 2017 and 2019 
(n=12 676).
MAIN OUTCOME MEASURES
Risks of clinical manifestations, healthcare resource 
use (including use of mechanical ventilation, 
admission to intensive care, and length of stay), and 
death, estimated using a doubly robust approach to 
build propensity scores that were then used along 
with covariates to adjust the outcome models.
RESULTS
Compared with seasonal influenza, covid-19 was 
associated with higher risk of acute kidney injury 
(odds ratio 1.52, 95% confidence interval 1.37 to 
1.69), incident renal replacement therapy (4.11, 3.13 
to 5.40), incident insulin use (1.86, 1.62 to 2.14), 
severe septic shock (4.04, 3.38 to 4.83), vasopressor 
use (3.95, 3.46 to 4.51), pulmonary embolism 
(1.50, 1.18 to 1.90), deep venous thrombosis (1.50, 
1.20 to 1.88), stroke (1.62, 1.17 to 2.24), acute 
myocarditis (7.82, 3.53 to 17.36), arrythmias and 
sudden cardiac death (1.76, 1.40 to 2.20), elevated 
troponin (1.75, 1.50 to 2.05), elevated aspartate 
aminotransferase (3.16, 2.91 to 3.43), elevated 
alanine aminotransferase (2.65, 2.43 to 2.88), and 
rhabdomyolysis (1.84, 1.54 to 2.18). Compared with 
seasonal influenza, covid-19 was also associated with 
higher risk of death, mechanical ventilator use, and 
admission to intensive care (hazard ratio 4.97, (95% 
confidence interval 4.42 to 5.58), 4.01 (3.53 to 4.54), 
and 2.41 (2.25 to 2.59), respectively) and 3.00 (2.20 
to 3.80) additional days of hospital stay. Differences 
in rates of death per 100 patients between covid-19 
and seasonal influenza were most pronounced in 
people over 75 years of age with chronic kidney 
disease or dementia and those with black race and 
obesity, diabetes, or chronic kidney disease.
CONCLUSIONS
Among people admitted to hospital, compared with 
seasonal influenza, covid-19 was associated with 
increased risk of extrapulmonary organ dysfunction, 
death, and increased health resource use. The 
findings may inform the global discussion about the 
comparative risks of covid-19 and seasonal influenza 
and may help the ongoing effort to manage the 
covid-19 global pandemic.
Introduction
The coronavirus disease 2019 (covid-19) global 
pandemic might be the most challenging health 
crisis of our lifetime. The number of infected people 
and number of deaths continue to grow worldwide.1 
Comparisons of clinical manifestations and mortality 
between covid-19 and seasonal influenza have been 
drawn by public health officials, policy makers, and 
the public at large. However, these comparisons have 
so far relied on data and mortality statistics obtained 
by disparate methods and are not based on an “apples 
with apples” comparison.2 A robust comparative 
approach would allow stakeholders to develop a 
deeper understanding of the health risks of covid-19 
(compared with the well known seasonal influenza) 
and to anticipate demand for healthcare services and 
project mortality with greater accuracy.
In this study, we leveraged the breadth and depth 
of the electronic healthcare databases of the US 
Department of Veterans Affairs (VA), which operates 
the largest nationally integrated healthcare delivery 
system in the US, to do a comparative evaluation 
of clinical manifestations and outcomes among 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Covid-19 is an emerging infectious disease caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), of which the predominant clinical 
presentation is respiratory disease
Evidence is accumulating that it is associated with extrapulmonary 
manifestations and high risk of healthcare use and death
Comparisons of clinical manifestations and mortality between covid-19 and 
seasonal influenza have been made using disparate data and statistical methods 
and do not represent “apples with apples” comparisons
WHAT THIS STUDY ADDS
Among people admitted to hospital, compared with seasonal influenza, 
covid-19 was associated with increased risk of various extrapulmonary clinical 
manifestations
Covid-19 was also associated with increased health resource use, including 
mechanical ventilator use, admission to intensive care, and length of hospital 
stay, and nearly five times the risk of death
The differences in death rates between covid-19 and seasonal influenza were 
most manifest in older adults with kidney disease or dementia and black people 
with obesity, diabetes, or kidney disease
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US veterans admitted to hospital with covid-19 
and seasonal influenza. This approach provides 
a comparative assessment between covid-19 and 
seasonal influenza and will inform the global 
discussion and effort to manage current and future 
waves of this global pandemic in which some waves 




We used the electronic healthcare databases of the 
US Department of Veterans Affairs, which operates 
the largest nationally integrated healthcare system 
in the United States—a veteran specific national 
health service—to discharged veterans of the US 
armed forces. The US Department of Veterans Affairs 
provides care at 1255 healthcare facilities, including 
170 VA medical centers (hospital systems) and 
1074 outpatient sites of care of varying complexity 
(Veterans Health Administration outpatient clinics) 
to more than nine million veterans enrolled in the VA. 
All enrolled veterans have access to the Department 
of Veterans Affairs’ comprehensive medical benefits 
package including inpatient hospital care; outpatient 
services; preventive, primary, and specialty care; 
prescriptions; mental healthcare; home healthcare; 
geriatric and extended care; medical equipment; and 
prosthetics.
Cohort
We selected patients from the Department of Veterans 
Affairs healthcare system with a positive laboratory 
test result for influenza between 1 January 2017 and 
31 December 2019 (n=54 281) or with a positive 
laboratory test for covid-19 between 1 February 2020 
and 17 June 2020 (n=9125). We identified patients 
with a hospital admission between five days before 
and 30 days after the positive test result (n=12 748 in 
seasonal influenza group; n=3641 in covid-19 group). 
For participants with both seasonal influenza and 
covid-19 hospital admission records (n=72), we used 
their first covid-19 admission records in the analyses. 
The final cohort consisted of 16 317 participants, 
including 12 676 participants in the seasonal influenza 
group and 3641 participants in the covid-19 group 
(supplementary figure S1). We defined time zero as the 
date of admission to hospital and followed participants 
until the first occurrence of 60 days after admission, 
death, or end of study follow-up (17 June 2020). After 
60 days of follow-up, 168 (1.33%) patients in the 
seasonal influenza group and 76 (2.08%) patients 
in the covid-19 group remained in hospital. The 
probability of patients remaining in hospital in the two 
groups is provided in supplementary figure S2.
Data sources
The Department of Veterans Affairs Corporate Data 
Warehouse (CDW) provided electronic health records 
from participants enrolled in the VA healthcare 
system.3-6 We used the CDW laboratory results domain 
to collect laboratory test information and the CDW 
inpatient encounters domains to collect information 
including diagnoses, procedures, and other aspects 
of healthcare use during a hospital admission.7 
We used the CDW pharmacy domain and CDW bar 
code medication administration domain to collect 
medication data and the CDW vital signs domain to 
collect vital measurements. We collected demographic 
information from the CDW patient domain and VA vital 
status database, as well as disease history from both 
the CDW inpatient encounter and outpatient encounter 
domains.8-10
Exposures
Exposures in the study were admission to hospital with 
seasonal influenza and admission to hospital with 
covid-19, defined on the basis of a positive laboratory 
test result for seasonal influenza or covid-19 with a 
hospital admission within five days before the test or 
within 30 days after the test.
Outcomes
The primary outcome of the study was time until 
death since hospital admission. We defined clinical 
outcomes including acute kidney injury, incident renal 
replacement therapy, incident insulin use, severe 
septic shock, vasopressor use, pulmonary embolism, 
deep venous thrombosis, stroke, acute myocarditis, 
arrythmias and sudden cardiac death, elevated 
troponin, elevated aspartate aminotransferase, elevated 
alanine aminotransferase, and rhabdomyolysis 
by using definitions based on laboratory data 
and diagnostic and procedure codes.6  11-18 
Outcomes related to healthcare use included time 
until mechanical ventilation, time until admission to 
intensive care unit (ICU), and length of stay in hospital, 
which we defined as days from admission until first 
discharge among patients discharged from hospital.
Covariates
Covariates in the study included demographics such 
as age, race (white, black, and other), and sex; history 
of diseases such as chronic lung disease, cancer, 
cardiovascular disease, cerebrovascular disease, 
dementia, diabetes mellitus, hypertension, and 
peripheral artery disease; history of use of drugs such 
as statins, angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers, and non-steroidal anti-
inflammatory drugs; smoking status (never, former, 
and current); and estimated glomerular filtration rate 
and body mass index (underweight <18.50, normal 
≥18.50-<25, overweight ≥25-<30, and obese ≥30) 
calculated from height and weight. We ascertained 
disease history during the year before admission to 
hospital and defined outpatient drug use by a record 
of prescription that provided medication within the 
30 days before the admission. We selected estimated 
glomerular filtration rate and body mass index from 
the measurement before and closest to the admission. 
When values of covariates were missing (0.18% of 
age, 2.56% of estimated glomerular filtration rate, 
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and 2.02% of body mass index), we applied mean 
imputation.
We also collected vital signs at admission, including 
heart rate, temperature, respiratory rate, blood oxygen 
concentration, systolic and diastolic blood pressure, 
and laboratory measurements including white blood 
cell count, hemoglobin, serum albumin, blood urea 
nitrogen, platelet count, bicarbonate, and lymphocyte 
percentage, on the basis of measurements during the 
hospital admission and closest to admission date and 
time.
Statistical analyses
We present the mean and standard deviation, frequency 
and percentage, or median and interquartile range, as 
appropriate, of the characteristics for patients admitted 
to hospital with seasonal influenza and covid-19. We 
made between group comparisons using χ2 tests for 
counts and t tests for continuous variables.
We used logistic regressions to examine the 
difference in clinical manifestations between seasonal 
influenza and covid-19. We estimated excess events 
per 100 patients based on difference in the probability 
of the event occurring if all participants had a hospital 
admission for covid-19 compared with if all participants 
had a seasonal influenza related admission. To adjust 
for confounding, we used doubly robust estimation 
for all models. We built a propensity score based on 
covariates including age, sex, race, smoking status, 
body mass index, estimated glomerular filtration rate, 
chronic lung diseases, cancer, cardiovascular diseases, 
cerebrovascular disease, dementia, diabetes mellitus, 
hypertension, peripheral artery disease, and use of 
statins, angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers, and non-steroidal anti-
inflammatory drugs. Doubly robust estimation adjusted 
for both the covariates and the propensity score in the 
outcome models.19 20 To evaluate the likelihood of 
violation of the positivity assumption, we plotted the 
propensity score distributions in two exposure groups 
(supplementary figure S3). We examined the balance 
of baseline characteristics between the covid-19 group 
and seasonal influenza group, and the result suggested 
that balance was achieved with the application of the 
propensity score (supplementary figures S3 and S4; 
supplementary table S1).
We constructed survival models with doubly robust 
estimation to examine the difference in risk of death 
between hospital admission for covid-19 and hospital 
admission for seasonal influenza. We estimated risk 
of mechanical ventilator use and admission to ICU on 
the basis of the Fine and Gray survival model, in which 
death before the occurrence of the event was considered 
a competing risk.21 For all survival outcomes, we 
evaluated proportional hazard assumptions and 
observed no indication of violation (supplementary 
figure S5). We estimated excess outcomes per 100 
patients on the basis of the differences in cumulative 
incidence at 60 days if all participants had a 
hospital admission for covid-19 compared with if all 
participants had a hospital admission for seasonal 
influenza.13 We also used linear regression to examine 
the difference in length of stay in patients discharged 
from hospital.
We aimed to identify groups of participants that were 
at the highest risk of death due to covid-19, as well as 
those groups that had the highest disparities between 
risk of death due to covid-19 and seasonal influenza. 
We did further survival analyses to investigate risk 
of death by comorbid condition and demographics 
(age ≤65, >65-≤75, >75; white, black race) pairs. We 
estimated death rates per 100 participants on the basis 
of the cumulative incidence function at 60 days if all 
participants had a hospital admission for covid-19 with 
a defined comorbid condition and demographic pair 
(for example, rate of death in those aged ≤65 and with 
cardiovascular disease). We then estimated differences 
in death rates between hospital admission for covid-19 
and hospital admission for seasonal influenza under 
each condition pair. Results are presented in heat 
maps, colored by the rate of death.
We did sensitivity analyses to test the robustness 
of the results. We estimated the risk (hazard ratios) 
of death, mechanical ventilation, and admission to 
ICU for covid-19 versus seasonal influenza in each 
influenza season included in the cohort (influenza 
season 2016-17, 2017-18, 2018-19, and 2019-20). 
We then examined the risks (hazard ratios) for covid-19 
versus influenza type A and type B, separately. 
Because influenza A subtypes may vary by season, 
we also examined the association of covid-19 versus 
influenza type A in each season. We examined the 
risks (hazard ratios) of outcomes for covid-19 versus 
influenza in patients with a record of vaccination for 
influenza and those without a record of vaccination. 
We estimated the risks within 30 days of admission 
to hospital and setting the time of positive test result 
as time zero. We examined the risks (hazard ratios) 
according to hospital bed occupancy and, separately, 
according to ICU bed occupancy in covid-19 patients. 
We updated the covariates during the follow-up 
and did time dependent analyses. We applied the 
overlap weighting method and the inverse probability 
weighting method. To remove potentially nosocomially 
acquired infections, we removed patients who had a 
first positive test after admission to hospital and then 
additionally removed those who had a first positive 
test on the first day of admission. We did analyses in 
subgroups based on sex, and, finally, we evaluated the 
association in subgroups according to smoking status 
and body mass index category.
We considered P values less than 0.05, 95% 
confidence intervals of the hazard ratio or odds ratio 
that did not cross 1, or 95% confidence intervals of the 
length of stay difference or event rate difference that 
did not cross 0 to be statistically significant. We used 
SAS Enterprise Guide version 7.1 for all analyses.
Patient and public involvement
No patients were involved in developing the hypothesis, 
the specific aims, or the research questions; nor 
were they involved in developing plans for design 
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or implementation of the study. No patients were 
involved in the interpretation or writing up of results. 
The study was conceived, designed, and conducted 
under the exigent circumstances of the covid-19 
global pandemic, which precluded patient and public 
engagement.
Results
A total of 12 676 people were admitted to hospital 
with seasonal influenza between 1 January 2017 and 
31 December 2019, and 3641 were admitted with 
covid-19 between 1 February 2020 and 17 June 2020. 
Table 1 describes the baseline demographic and health 
characteristics. The percentage of black patients 
admitted with covid-19 (49.8%) was more than double 
the percentage admitted with seasonal influenza 
(22.0%); the percentages of patients with obesity, 
dementia, and diabetes mellitus were higher in the 
covid-19 group. The percentages of people who were 
current smokers or who had cancer, cardiovascular 
disease, chronic lung disease, and use of angiotensin 
converting enzyme inhibitors or angiotensin receptor 
blockers and statins was higher in the seasonal 
influenza group (table 1). 
Differences in clinical manifestations of covid-19 
versus seasonal influenza
We then comparatively evaluated the clinical 
manifestations of covid-19 versus those of seasonal 
influenza. Table 2 shows the number of events in 
each group, the unadjusted and adjusted odds ratios, 
and the excess number of outcomes per 100 patients 
admitted to hospital with covid-19 compared with 
seasonal influenza. Compared with people admitted to 
hospital with seasonal influenza, we observed a graded 
association between covid-19 and risk of acute kidney 
injury; the odds of the association increased with 
increasing severity of acute kidney injury, and we also 
saw an increased risk of incident renal replacement 
therapy. Covid-19 was also associated with increased 
risk of incident insulin use, severe septic shock, 
vasopressor use, pulmonary embolism, deep venous 
thrombosis, stroke, acute myocarditis, arrythmias 
and sudden cardiac death, elevated troponin, 
elevated aspartate aminotransferase, elevated alanine 
aminotransferase, and rhabdomyolysis.
Differences in risk of death and health resource use 
for covid-19 versus seasonal influenza
Table 3 and table 4 show the number of deaths in each 
group, unadjusted and adjusted hazard ratios, and the 
number of excess deaths per 100 patients admitted 
to hospital with covid-19 compared with seasonal 
influenza. Compared with people admitted to hospital 
with seasonal influenza, admission with covid-19 was 
associated with increased risk of death; we observed 
16.85 (95% confidence interval 14.85 to 18.99) 
excess deaths per 100 patients due to covid-19. Health 
resource use was much more pronounced for covid-19 
compared with seasonal influenza. Covid-19 was 
associated with significantly higher risk of mechanical 
ventilation use, admission to ICU, and prolonged 
length of hospital stay (table 3, table 4, fig 1, and fig 2).
Rates of death by age, race, and comorbid condition
Figure 3 and supplementary table S2a show estimated 
rates of death with covid-19 by age, race, and comorbid 
condition. Death rates were generally highest in older 
and black individuals. Excess rates of death per 
100 people with covid-19 (compared with seasonal 
influenza) were most pronounced in adults older than 
75 years with chronic kidney disease or dementia 
and in black people with obesity, diabetes, or chronic 
kidney disease (fig 3 and supplementary table S2b).
Sensitivity analyses
We did several sensitivity analyses to test the robustness 
of our results (fig 4 and supplementary table S3). 
Firstly, because mortality from seasonal influenza may 
vary by season, we developed sensitivity analyses to 
examine the risk of death and health resource use in 
covid-19 patients compared with those admitted with 
influenza in each season (2016-17, 2017-18, 2018-
19, 2019-20) separately; the results were consistent. 
Secondly, the results were also consistent when 
we evaluated the risk of death and resource use for 
covid-19 compared with influenza A and B, separately. 
Thirdly, because subtypes of influenza A may have 
differential effects on health outcomes and because 
the predominant subtype of influenza A may vary by 
season, we examined the association of covid-19 versus 
influenza A in each season; the results suggested that 
compared with influenza A, covid-19 was associated 
with increased risk of health resource use and death 
in each of the examined seasons (supplementary table 
S4). Fourthly, the increased risk in covid-19 versus 
seasonal influenza was observed in analyses in which 
the reference group was those influenza patients who 
received an influenza vaccine and, separately, those 
who did not receive an influenza vaccine. Fifthly, 
analyses that evaluated the risk of death in the first 30 
days and, separately, analyses that considered the date 
of testing positive for influenza or covid-19 as time zero 
yielded consistent results.
Sixthly, because a putative relation may exist 
between hospital bed occupancy—an indicator of 
how overwhelmed the hospital system is—and health 
outcomes, we examined the risk of death and health 
resource use for covid-19 versus seasonal influenza 
according to hospital bed occupancy (<20%, 20-
<40%, 40-<60%, and 60-77.82%, the maximum 
observed hospital bed occupancy in our cohort) and, 
separately, according to ICU bed occupancy (<20%, 
20-<40%, 40-<60%, 60-<80%, and 80-102.38%, 
the maximum observed ICU bed occupancy in our 
cohort); the results were consistent with the primary 
analyses. The distributions of occupancy of hospital 
beds and ICU beds are provided in supplementary 
figure S6. Seventhly, the results were also consistent 
in time dependent analyses in which covariates were 
updated during follow-up. Eighthly, we considered the 
overlap weighting method and the inverse probability 
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weighting method as two alternatives to our primary 
approach (the doubly robust method); both alternative 
methods yielded estimates consistent with the 
primary approach. Ninthly, to eliminate concern about 
nosocomially acquired seasonal influenza or covid-19 
infections, we did analyses in which we removed 
patients who had a positive test while in hospital 
and restricted cohort entry to those with a positive 
influenza or covid-19 test before and including the first 
day of hospital admission; results were consistent with 
those in the primary analyses and were also consistent 
in analyses considering patients with a positive 
test before admission. Tenthly, because our cohort 
comprised mostly male US veterans, and to examine 
whether the observed associations were also evident 
among female patients, we did analyses in subgroups 
based on sex; the results were consistent in both 
male and female subgroups. Finally, to test whether 
the observed associations were evident in smokers 
and non-smokers and, separately, among people 
with normal weight and obesity, we evaluated the 
association in subgroups according to smoking status 
and body mass index category; the results suggested 
that compared with seasonal influenza, covid-19 was 
Table 1 | Baseline and admission characteristics of patients admitted to hospital with seasonal influenza and 
coronavirus disease 2019 (covid-19). Values are numbers (percentages) unless stated otherwise






Mean (SD) age, years 69.98 (12.91) 70.25 (12.8) 69.03 (13.4) <0.001
Sex: 0.65
 Male 15 432 (94.6) 11 994 (94.6) 3438 (94.4)
 Female 885 (5.42 682 (5.4) 203 (5.6)
Race: <0.001 
 White 10 975 (67.3) 9318 (73.5) 1657 (45.5)
 Black 4599 (28.2) 2787 (22.0) 1812 (49.8)
 Other 743 (4.6) 571 (4.5) 172 (4.7)
Smoking: <0.001 
 Never 7673 (47.0) 5694 (44.9) 1979 (54.4)
 Former 4420 (27.1) 3315 (26.2) 1105 (30.4)
 Current 4224 (25.9) 3667 (28.9) 557 (15.3)
Body mass index: <0.001 
  Underweight (<18.5) 550 (3.4) 441 (3.5) 109 (3.0)
 Normal (18.5 to <25) 4093 (25.1) 3333 (26.3) 760 (20.9)
 Overweight (25 to <30) 4872 (29.9) 3829 (30.2) 1043 (28.7)
 Obese (≥30) 6802 (41.7) 5073 (40.0) 1729 (47.5)
Mean (SD) eGFR, mL/min/1.73m2 63.51 (27.3) 63.57 (26.6) 63.30 (29.6) 0.63
Chronic kidney disease 6994 (42.9) 5425 (42.8) 1569 (43.1) 0.75
Cancer 2788 (17.1) 2258 (17.8) 530 (14.6) <0.001
Cerebrovascular disease 2373 (14.5) 1817 (14.3) 556 (15.37) 0.16
Cardiovascular disease 6134 (37.6) 5007 (39.5) 1127 (31.0) <0.001
Dementia 2403 (14.7) 1693 (13.4) 710 (19.5) <0.001
Diabetes mellitus 7135 (43.7) 5418 (42.7) 1717 (47.2) <0.001
Hypertension 11 931 (73.1) 9277 (73.2) 2654 (72.9) 0.72
Chronic lung disease 6160 (37.8) 5271 (41.6) 889 (24.4) <0.001
Peripheral artery disease 764 (4.7) 610 (4.8) 154 (4.2) 0.14
Statins 7511 (46.0) 6114 (48.2) 1397 (38.4) <0.001
ACE/ARB 5579 (34.2) 4603 (36.3) 976 (26.8) <0.001
NSAIDs 1842 (11.29) 1439 (11.4) 403 (11.1) 0.63
Selected vital signs on admission*
Median (IQR) heart rate, beats per min 87 (75-100) 88 (76-101) 85 (75-97) <0.001
Median (IQR) temperature, °C 36.9 (36.6-37.5) 36.9 (36.6-37.5) 37.1 (34.4-36.7) <0.001
Temperature >38°C 2161 (13.3) 1627 (12.9) 534 (14.9) 0.002
Median (IQR) respiratory rate, breaths per min 18 (18-20) 18 (18-20) 18 (18-20) <0.001
Median (IQR) oxygen concentration, % 95 (93-97) 95 (93-97) 96 (94-98) <0.001
Oxygen concentration <95% 6104 (38.2) 4969 (40.0) 1135 (32.2) <0.001
Median (IQR) systolic blood pressure, mm Hg 131 (116-148) 131 (116-148) 131 (117-146) 0.24
Median (IQR) diastolic blood pressure, mm Hg 74 (65-82) 74 (65-82) 75 (67-83) <0.001
Selected laboratory measurements on admission*
Median (IQR) white blood cell count, ×109/L 7.1 (5.3-9.7) 7.4 (5.5-10.0) 6.2 (4.7-8.3) 0.001
Median (IQR) hemoglobin, g/L 131 (116-145) 131 (116-145) 131 (115-144) 0.02
Median (IQR) serum albumin, g/L 36 (31-39) 36 (32-39) 35 (30-38) <0.001
Median (IQR) blood urea nitrogen, mmol/L 6.8 (5.0-10.0) 6.8 (5.0-9.6) 7.1 (5.0-12.1) <0.001
Median (IQR) platelet count, ×109/L 185 (144-237) 182 (142-233) 193 (149-252) <0.001
Median (IQR) bicarbonate, mmol/L 25 (23-27) 25 (23-27) 25 (23-28) <0.001
Median (IQR) lymphocytes, % 12.7 (7.8-20.2) 11.9 (7.3-19.0) 15.8 (10.0-23.4) <0.001
ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; eGFR=estimated glomerular filtration rate; IQR=interquartile range; 
NSAID=non-steroidal anti-inflammatory drug.
*Vital signs and laboratory measurements recorded after and closest to admission date and time.
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associated with increased risk of death and health 
resource use regardless of smoking and body mass 
index status (fig 4 and supplementary table S3).
Discussion
In this work, we provide a comparative evaluation 
of the clinical manifestations and outcomes in a 
national cohort of patients admitted to hospital with 
covid-19 or seasonal influenza. Our results suggest 
that compared with seasonal influenza, covid-19 
was associated with higher risk of acute kidney 
injury, incident renal replacement therapy, incident 
insulin use, severe septic shock, vasopressor use, 
pulmonary embolism, deep venous thrombosis, 
stroke, acute myocarditis, arrythmias and sudden 
cardiac death, elevated troponin, elevated aspartate 
aminotransferase, elevated alanine aminotransferase, 
and rhabdomyolysis. Covid-19 was also associated 
with increased risk of death, need for mechanical 
ventilation, and admission to ICU and prolonged length 
of hospital stay. Excess rates of death for covid-19 (in 
excess of those for seasonal influenza) were highest in 






Unadjusted OR*  
(95% CI)
Adjusted OR*†  
(95% CI)
Excess outcomes per 
100 patients*‡ (95% CI)
Any acute kidney injury 3670 (29.0) 1355 (37.2) 1.46 (1.35 to 1.57) 1.52 (1.37 to 1.69) 5.81 (5.35 to 6.27)
Acute kidney injury stage 2 or above 638 (5.0) 538 (14.8) 3.27 (2.90 to 3.69) 3.16 (2.74 to 3.64) 8.06 (6.49 to 9.85)
Acute kidney injury stage 3 408 (3.2) 397 (10.9) 3.68 (3.19 to 4.25) 3.43 (2.90 to 4.06) 5.97 (4.57 to 7.66)
Incident renal replacement therapy§ 113/12 128 (0.9) 160/3430 (4.7) 5.20 (4.08 to 6.64) 4.11 (3.13 to 5.40) 2.77 (1.63 to 4.63)
Incident insulin use¶ 1048/8484 (12.4) 555/2412 (23.0) 2.12 (1.89 to 2.38) 1.86 (1.62 to 2.14) 9.35 (8.31 to 10.29)
Severe septic shock 300 (2.4) 319 (8.8) 3.96 (3.37 to 4.66) 4.04 (3.38 to 4.83) 6.36 (4.48 to 8.87)
Vasopressor use 613 (4.8) 595 (16.3) 3.84 (3.41 to 4.33) 3.95 (3.46 to 4.51) 11.47 (9.10 to 14.22)
Pulmonary embolism 262 (2.1) 118 (3.2) 1.59 (1.27 to 1.98) 1.50 (1.18 to 1.90) 1.00 (0.59 to 1.69)
Deep venous thrombosis 285 (2.3) 141 (3.9) 1.75 (1.43 to 2.15) 1.50 (1.20 to 1.88) 1.13 (0.69 to 1.83)
Stroke 124 (1.0) 69 (1.9) 1.96 (1.45 to 2.63) 1.62 (1.17 to 2.24) 0.62 (0.30 to 1.25)
Acute myocarditis 10 (0.1) 23 (0.6) 8.05 (3.83 to 16.92) 7.82 (3.53 to 17.36) 0.53 (0.11 to 2.63)
Arrythmias and sudden cardiac death 275 (2.2) 138 (3.8) 1.78 (1.44 to 2.19) 1.76 (1.40 to 2.20) 1.57 (0.97 to 2.51)
Troponin >0.4 ng/mL 654 (5.2) 311 (8.5) 1.73 (1.51 to 1.99) 1.75 (1.50 to 2.05) 3.37 (2.50 to 4.47)
Aspartate aminotransferase:
 >40 IU/L 3694 (29.1) 2104 (57.8) 3.33 (3.08 to 3.59) 3.16 (2.91 to 3.43) 27.00 (26.00 to 27.71)
 >5 times upper limit of normal** 279 (2.2) 204 (5.6) 2.64 (2.19 to 3.17) 2.38 (1.94 to 2.91) 2.90 (1.90 to 4.35)
Alanine aminotransferase:
 >40 IU/L 3154 (24.9) 1697 (46.6) 2.64 (2.44 to 2.84) 2.65 (2.43 to 2.88) 21.12 (19.81 to 22.26)
 >5 times upper limit of normal †† 311 (2.5) 309 (8.5) 3.46 (2.95 to 4.06) 3.33 (2.80 to 3.97) 5.54 (3.90 to 7.76)
Rhabdomyolysis:
 CPK >1000 IU/L 411 (3.2) 274 (7.5) 2.43 (2.08 to 2.84) 1.84 (1.54 to 2.18) 2.65 (1.87 to 3.72)
 CPK >5000 IU/L 94 (0.7) 43 (1.2) 1.60 (1.11 to 2.30) 1.20 (0.81 to 1.77) 0.15 (−0.06 to 0.42)
 CPK >5× upper limit of normal ‡‡ 288 (2.3) 181 (5.0) 2.25 (1.86 to 2.72) 1.66 (1.35 to 2.04) 1.53 (0.98 to 2.35)
CPK=creatine phosphokinase; OR=odds ratio.
*Seasonal influenza group served as reference.
†Models adjusted for age, sex, race, smoking status, body mass index, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease, 
dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of statins, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, and non-steroidal anti-
inflammatory drugs.
‡Excess outcomes per 100 patients due to covid-19 compared with seasonal influenza.
§Among patients without history of renal replacement therapy before hospital admission (n=15 558).
¶Among patients without history of diabetes treatment before hospital admission (n=10 896).
**Defined as 240 IU/L for males and 215 IU/L for females.
††Defined as 165 IU/L for males and 125 IU/L for females.
‡‡Defined as 1540 IU/L for males and 960 IU/L for females.











Excess outcomes per 100 
patients*‡ (95% CI)
Death No (%) 674 (5.3) 676 (18.6) 4.55 (4.09 to 5.07) 4.97 (4.42 to 5.58) 16.85 (14.85 to 18.99)Median (IQR) days till event§ 18 (6-17) 10 (6-17)
Mechanical ventilator use¶ No (%) 529 (4.2) 545 (15.0) 3.93 (3.49 to 4.42) 4.01 (3.53 to 4.54) 11.29 (9.62 to 13.14)Median (IQR) days till event** 1 (0-4) 2 (0-5)
ICU admission¶ No (%) 2353 (18.6) 1341 (36.8) 2.30 (2.16 to 2.46) 2.41 (2.25 to 2.59) 19.80 (17.81 to 21.87)Median (IQR) days till event†† 1 (0-5) 0 (0-4)
HR=hazard ratio; ICU=intensive care unit; IQR=interquartile range.
*Seasonal influenza group served as reference.
†Models adjusted for age, sex, race, smoking status, body mass index, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease, 
dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of statins, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, and non-steroidal anti-
inflammatory drugs.
‡Excess outcome per 100 patients due to covid-19 compared with seasonal influenza.
§ Among patients who died.
¶Death before event was considered as competing risk.
**Among patients who used mechanical ventilation.
††Among patients who had ICU admission.
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adults older than 75 years with chronic kidney disease 
and dementia and in black patients with obesity, 
diabetes mellitus, and chronic kidney disease. The 
results were robust to challenge in multiple sensitivity 
analyses.
Contextual evaluation of findings
As our understanding of covid-19 is evolving, the 
fact that, although the virus preferentially infects 
cells in the respiratory tract, it may also be detected 
in multiple organs, suggesting broad extrapulmonary 
organotropism, is becoming increasingly clear.22 23 
Covid-19 seems to have a kidney tropic effect; early 
observations suggested high rates of acute kidney 
injury and need for renal replacement therapy among 
patients with covid-19.22-25 Here, we show that risks 
of acute kidney injury and incident renal replacement 
therapy were higher with covid-19 than seasonal 
influenza. In our cohort, 15.0% of patients with 
covid-19 needed mechanical ventilation, generally 
consistent with the range of 12% to 24% reported 
in other US studies of covid-19.26-28 Recent reports 
suggested a bidirectional relation between covid-19 
and diabetes mellitus, in that diabetes may predispose 
to covid-19 and that a diagnosis of covid-19 may result 
in derangement in insulin and glucose homeostasis 
and new onset of diabetes.29 30 Our findings of higher 
risk of incident insulin use among patients who were 
not taking any treatment for diabetes mellitus before 
hospital admission with covid-19 suggests the need for 
greater attention to management of glucose in patients 
with covid-19 and the need for long term follow-up to 
gain a better understanding of the chronicity of these 
acute disturbances in glucose homeostasis.29 Risks 
of severe septic shock and vasopressor use were also 
higher in the covid-19 group, consistent with reports of 
septic shock in patients with covid-19.31 We also report 
increased risk of pulmonary embolism, deep venous 
thrombosis, and stroke compared with seasonal 
influenza; clarity about the underlying biologic 
mechanism of a prothrombotic hypercoagulable state 
in covid-19 is evolving.32-36 The findings of increased 
risk of acute myocarditis, arrythmias and sudden 
cardiac death, and elevated troponin suggest that 
covid-19 may portend serious cardiac complications. 
Risk of elevated transaminases and rhabdomyolysis 
was also increased among patients with covid-19; the 
underlying pathophysiology of these abnormalities is 
not yet entirely clear. Our approach for the comparative 
evaluation of the acute clinical manifestations of 
covid-19 versus seasonal influenza was based on a 
priori knowledge; however, as our understanding 
of the clinical manifestations of covid-19 deepens, 
additional important differences in the clinical 
sequalae of these two diseases may come to light and 
may be investigated in future research.
Many of the acute clinical manifestations of covid-19 
described in this report are disease states that need 
chronic management (for example, new onset diabetes, 















































































































0 10 20 30 40 50 60
Fig 1 | Adjusted cumulative incidence rate (with 95% CI) of death, mechanical ventilator 
use, and admission to intensive care unit (ICU) per 100 patients admitted to hospital 
with seasonal influenza and coronavirus disease 2019 (covid-19)
Table 4 | Length of hospital stay in patients admitted to hospital with coronavirus disease 2019 (covid-19) versus 






Unadjusted days  
difference* (95% CI)
Adjusted days difference*† 
(95% CI)
Length of hospital 
stay, days
Median (IQR) 3 (2-6) 6 (3-12) 3.11 (2.36 to 3.7) 3.00 (2.20 to 3.80)Mean (SD) 7 (19.00) 10 (10.99)
IQR=interquartile range.
*Seasonal influenza group served as reference.
†Models adjusted for age, sex, race, smoking status, body mass index, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular 
disease, cerebrovascular disease, dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of statins, angiotensin converting enzyme 
inhibitors/angiotensin II receptor blockers, and non-steroidal anti-inflammatory drugs.
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suggesting that some acute symptoms of covid-19 may 
linger far beyond the acute illness and that recovery may 
be protracted and incomplete in many “long haulers.” 
Taken together, these observations suggest that, 
beyond the acute setting, a greater understanding of 
the long term health trajectories of patients with “long 
covid-19” and care strategies to optimize wellness and 
reduce the burden of chronic and permanent health 
loss are needed to lessen the overall health, societal, 
and economic toll of this pandemic.
We observed much higher rates of death among 
patients admitted to hospital with covid-19 than with 
seasonal influenza. We also report that in adjusted 
models using the doubly robust approach, the risk of 
death in covid-19 patients was nearly fivefold higher 
than in those in the seasonal influenza group. We 
estimated that compared with seasonal influenza, 
covid-19 was associated with 16.85 (95% confidence 
interval 14.85 to 18.99) excess deaths per 100 patients. 
Our results also suggest significantly increased risk 
of mechanical ventilation use, ICU admission, and 
prolonged length of stay. Our estimates provide 
an “apples with apples” comparative quantitative 
assessment of the magnitude of risk of death (and other 
health outcomes) in patients admitted to hospital with 
covid-19 and seasonal influenza. The estimates may 
help to inform efforts to manage the ongoing covid-19 
global pandemic in which some surge in activity (wave) 
may coincide with seasonal influenza.
Our heatmap approach, which provides adjusted 
estimates of the rates of death by age, race, and 
comorbid condition, shows that differences in rates of 
death between covid-19 and seasonal influenza (excess 
rates of death in covid-19) are most pronounced in 
older adults, among black people, and in those with 
dementia, diabetes mellitus, obesity, and kidney 
disease, suggesting that a more targeted prevention 
effort aimed at these high risk populations may be 
needed to reduce mortality rates.
Several other considerations merit discussion. 
Although we balanced the two groups according to 
demographic and health characteristics to optimize the 
comparative evaluation of the clinical characteristics 
and outcomes of covid-19 versus seasonal influenza, 
increased awareness of covid-19 may have resulted in 
greater ascertainment of covid-19 infections, whereby 
less severe cases of covid-19 relative to seasonal 
influenza would be diagnosed and possibly admitted 
to hospital, and relatively less historical ascertainment 
of seasonal influenza, whereby milder influenza cases 
may not have been diagnosed, enriching the seasonal 
Death
Mechanical ventilator use
Intensive care unit admission
16.85 (14.85 to 18.99)
11.29 (9.62 to 13.14)
19.80 (17.81 to 21.87)










3.00 (2.20 to 3.80)




stay (days) (95% CI)
Fig 2 | Risks of death and healthcare resource use in patients admitted to hospital with 
coronavirus disease 2019 (covid-19) versus seasonal influenza. Models were adjusted 
for age, sex, race, smoking status, body mass index, estimated glomerular filtration 
rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease, 
dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of 
statins, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers and 
non-steroidal anti-inflammatory drugs. Seasonal influenza group served as reference 













Deaths per 100 patients Excess deaths per 100 patients
Deaths Excess deaths
Overall ≤65 65-75 >75 White Black
10 15 20 25 30 35 10 15 20 25 305
Overall ≤65 65-75 >75 White Black
Fig 3 | Rates of death in patients admitted to hospital with coronavirus disease 2019 (covid-19) (left), and excess deaths compared with patients 
admitted with seasonal influenza (right), by age (≤65, 65-75, >75 years), race (white, black), and comorbid condition. Number in each cell represents 
rate of death or excess deaths per 100 patients admitted with covid-19, given conditions. Lighter colored cells indicate lower death rates or smaller 
differences, and darker colored cells indicate higher death rates or larger differences
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Fig 4 | Risks of death and healthcare resource use in patients admitted to hospital with coronavirus disease 2019 (covid-19) versus seasonal 
influenza. Seasonal influenza group served as reference. BMI=body mass index; ICU=intensive care unit; T0=time zero. *Models adjusted for age, 
sex, race, smoking status, BMI, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease, 
dementia, diabetes mellitus, hypertension, peripheral artery disease, use of statins, angiotensin converting enzyme inhibitors/angiotensin II 
receptor blockers, and non-steroidal anti-inflammatory drugs. †Included seasonal influenza patients between 1 Jan 2017 and 31 Aug 2017 in cohort. 
‡Included seasonal influenza patients between 1 Sept 2017 and 31 Aug 2018 in cohort. §Included seasonal influenza patients between 1 Sept 2018 
and 31 Aug 2019 in cohort. ¶Included seasonal influenza patients between 1 Sept 2019 and 31 Dec 2019 in cohort
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influenza group with relatively sicker patients and 
resulting in underestimation of the risk of outcomes 
in covid-19 compared with seasonal influenza. Also, 
relaxed admission criteria and reduced threshold 
for admission in the covid-19 era—primarily driven 
by heightened concerns about the virus—may have 
resulted in admission of less sick people with covid-19, 
which may have resulted in underestimation of risk of 
covid-19 versus seasonal influenza. Health outcomes 
of patients admitted to hospital may deteriorate as 
hospitals become overwhelmed; if this existed in our 
data, it may have resulted in overestimation of the 
risk of adverse outcomes in covid-19 versus seasonal 
influenza. However, although the pandemic exacted 
a serious challenge to the VA hospital system, our 
examination of weekly average bed occupancy and 
weekly average ICU bed occupancy did not suggest that 
the system was substantially strained (supplementary 
figure S6), and we consistently observed that covid-19 
was associated with increased risk of adverse 
outcomes regardless of level of occupancy and the 
excess risk was evident even in low occupancy. In 
our comparative evaluation, we considered several 
seasons of influenza, and the predominant subtype 
of seasonal influenza may vary by season; influenza 
A (H3N2) predominated in 2016-17 and 2017-18, 
influenza A(H1N1)pdm09 predominated in 2018-
19, and influenza B predominated early in the 2019-
20 season. H3N2 predominant seasons have been 
associated with more severe illness and mortality, 
especially in older adults, relative to seasons during 
which H1N1 or B viruses predominated.37 38 In our 
evaluation, we did not identify appreciable differences 
in risk of covid-19 versus seasonal influenza by season 
or by influenza type (A or B). However, our data did not 
contain enough information to allow a comparative 
evaluation according to influenza subtype; evaluation 
of the risks of death, mechanical ventilation, and 
ICU admission for covid-19 versus influenza type A 
by season yielded consistently higher risk of adverse 
events for covid-19. Effect of sex, body mass index, and 
smoking status on health outcomes may be different in 
covid-19 and seasonal influenza.39-45 Our analyses of 
subgroups based on sex, body mass index category, 
and smoking status showed consistently that covid-19 
was associated with worse outcomes than seasonal 
influenza, but further studies are needed to gain a 
fuller understanding of how these characteristics may 
differentially influence health outcomes in patients 
with covid-19 and seasonal influenza.
Limitations and strengths of study
This study has several limitations. We relied on data 
from electronic health records to do this comparative 
evaluation, and, although we used validated 
definitions, inaccurate measurements of variables 
and misclassification bias may not be completely 
eliminated. We used a doubly robust approach to 
examine the risk of clinical manifestations and health 
outcomes for covid-19 versus seasonal influenza,19 but 
we cannot completely exclude the possibility of residual 
confounding. Our cohort comprised US veterans who 
were admitted to hospital for seasonal influenza or 
covid-19 and included mostly older white males, 
so our results may not be generalizable to broader 
populations such as younger and healthier people. 
Although we provide estimates of the adjusted absolute 
rates of death according to age, race, and comorbid 
condition to facilitate comparative evaluation of risk in 
these groups, absolute rates may be lower in younger 
and healthier populations. Our evaluation included 
a comparative assessment of clinical manifestations 
and outcomes of seasonal influenza and covid-19; 
however, a pandemic influenza may have different 
clinical manifestations and outcome profile. Finally, as 
this pandemic continues to evolve, our understanding 
of the epidemiology, clinical characteristics, and 
outcomes of covid-19 will continue to evolve; in 
particular, we note that care of covid-19 patients is 
evolving rapidly, including discovery and use of new 
therapeutics, and a vaccine is anticipated sometime 
soon. Both drivers (improved care and vaccine 
availability) will likely result in amelioration of health 
outcomes among people with covid-19.
The study also has several strengths. We designed the 
study to evaluate risk of death among people admitted 
to hospital with covid-19 and seasonal influenza in 
the same nationally integrated healthcare delivery 
system designed to give equal access to care for eligible 
veterans, which enhances the ability to establish a 
comparative evaluation of risk. The multidimensional 
nature and depth of VA data facilitate ascertainment 
of medical conditions not only through diagnostic 
or procedure codes but also through laboratory data 
(for example, serum creatinine to define acute kidney 
injury, estimated glomerular filtration rate to define 
chronic kidney disease, creatine phosphokinase to 
define rhabdomyolysis), vital signs (including body 
mass index), vital status, and medication records (for 
example, vasopressor use, insulin requirements). 
Finally, we used a doubly robust approach to examine 
the association between exposures and outcomes, 
and our results were robust to challenge in multiple 
sensitivity analyses including the application of two 
alternative methods (overlap weighting method and 
inverse probability weighting method).
Conclusions
In sum, our results suggest that compared with patients 
admitted to hospital with seasonal influenza, those 
admitted with covid-19 have increased risk of systemic 
clinical manifestations (including higher risk of acute 
kidney injury, incident renal replacement therapy, 
incident insulin use, severe septic shock, vasopressor 
use, pulmonary embolism, deep venous thrombosis, 
stroke, acute myocarditis, arrythmias and sudden 
cardiac death, elevated troponin, elevated aspartate 
aminotransferase, elevated alanine aminotransferase, 
and rhabdomyolysis), increased risk of death, and 
higher need for healthcare resources (mechanical 
ventilation, ICU admission, length of hospital stay). 
Rates of death for covid-19 in excess of rates for 
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seasonal influenza were highest in adults aged over 
75 years with chronic kidney disease and dementia 
and in black people with obesity, diabetes, and 
chronic kidney disease. Our results inform the global 
discussion about the comparative risks of covid-19 and 
seasonal influenza and may guide efforts to manage 
this ongoing global pandemic.
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